The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prospective molecular evaluation of small cell lung cancer (SCLC) utilizing the comprehensive mutation analysis program at Memorial Sloan-Kettering Cancer Center (MSKCC).
Maria Catherine Pietanza
No relevant relationships to disclose
Anna M. Varghese
No relevant relationships to disclose
Helen H. Won
No relevant relationships to disclose
Lu Wang
No relevant relationships to disclose
Natasha Rekhtman
No relevant relationships to disclose
Lee M. Krug
No relevant relationships to disclose
Paul K. Paik
Research Funding - AstraZeneca; Pfizer
Gregory J. Riely
Consultant or Advisory Role - Foundation Medicine
Maureen Frances Zakowski
No relevant relationships to disclose
Marc Ladanyi
No relevant relationships to disclose
Michael F. Berger
No relevant relationships to disclose
Mark G. Kris
No relevant relationships to disclose